NACL Q1: consolidated PAT up 60% to ₹20.8 Cr on margin expansion as revenue slips 14%

NACL Industries' Q1 FY27 (quarter ended 30 June 2026) is a bottom-line story: consolidated net profit rose 59.8% year-on-year to ₹20.84 Cr from ₹13.04 Cr, even as revenue from operations fell 14.1% to ₹383.33 Cr (₹448.36 Cr a year ago). The print is clean — no exceptional items this quarter, so the profit jump is not flattered by one-offs; the ₹17.45 Cr consolidated exceptional loss tied to discontinuing certain under-development products belongs to FY26. The profit surge is entirely margin-led: total consolidated expenses fell ~17% YoY (₹431.45 Cr to ₹356.89 Cr), outpacing the 14% revenue decline, lifting net margin to 5.4% from 2.9%. Sequentially the quarter is a turnaround — from a ₹0.86 Cr net loss in Q4 FY26 to a ₹20.84 Cr profit — with revenue up 6.7% QoQ, though for an agrochemical (crop-protection) business the April–June pre-kharif window is seasonally the strongest quarter, so part of the sequential jump is seasonality rather than a fresh demand inflection. A notable wrinkle sits below the profit line: EPS eased to ₹0.60 from ₹0.65 YoY despite the higher absolute profit, because the December 2025 rights issue (32.5M new ₹1 shares) expanded the share count faster than earnings grew — per-share metrics are diluted even as the P&L improved. Standalone profit (₹23.57 Cr, +65% YoY) ran ahead of consolidated, the ~₹2.7 Cr gap reflecting subsidiary losses (one subsidiary posted a ₹3.41 Cr net loss; the associate contributed nil). Both bases tell the same story — revenue down low-double-digits, profit up ~60% on cost-led margin gains — so there is no material standalone/consolidated divergence. Management gives no formal guidance and there is no prior concall or outlook on record, so the print can only be judged on its own merits; no analyst consensus is published for a name this size, so a beat/miss versus street cannot be established. Alongside the results the Board approved divesting the company's entire stake in associate Nasense Labs to Mr. K. Satyanarayana Raju for ₹8.15 Cr (expected to close within three months) and cleared the deviation statement on Rights Issue fund utilisation — ₹24.45 Cr of the rights proceeds remains unutilised, parked in an earmarked bank account. The core question the numbers leave open is whether the topline contraction is demand-driven or a deliberate mix/portfolio shift, and whether the fresh margin level holds.